HK1220706A1 - 特異性結合蛋白及其用途 - Google Patents

特異性結合蛋白及其用途

Info

Publication number
HK1220706A1
HK1220706A1 HK16108847.0A HK16108847A HK1220706A1 HK 1220706 A1 HK1220706 A1 HK 1220706A1 HK 16108847 A HK16108847 A HK 16108847A HK 1220706 A1 HK1220706 A1 HK 1220706A1
Authority
HK
Hong Kong
Prior art keywords
specific binding
binding proteins
proteins
specific
binding
Prior art date
Application number
HK16108847.0A
Other languages
English (en)
Inventor
J Old Lloyd
Grant Jonhs Terrance
Panousis Con
Mark Scott Andrew
Renner Christoph
Ritter Gerd
Jungbluth Achim
Stockert Elizabeth
Collins Peter
K Cavenee Webster
Su Huang Huei-Jen
Wilks Burgess Antony
Collins Nice Edouard
Murray Anne
Mark George
Original Assignee
Ludwig Inst For Cancer Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42077108&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1220706(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ludwig Inst For Cancer Res Ltd filed Critical Ludwig Inst For Cancer Res Ltd
Publication of HK1220706A1 publication Critical patent/HK1220706A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1078—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an immunoglobulin, i.e. being an (anti)-anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK16108847.0A 2009-02-18 2016-07-25 特異性結合蛋白及其用途 HK1220706A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/388,504 US20100056762A1 (en) 2001-05-11 2009-02-18 Specific binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
HK1220706A1 true HK1220706A1 (zh) 2017-05-12

Family

ID=42077108

Family Applications (3)

Application Number Title Priority Date Filing Date
HK15107189.9A HK1206752A1 (zh) 2009-02-18 2015-07-28 特異性結合蛋白及其用途
HK16102177.3A HK1214278A1 (zh) 2009-02-18 2016-02-25 特異性結合蛋白及其用途
HK16108847.0A HK1220706A1 (zh) 2009-02-18 2016-07-25 特異性結合蛋白及其用途

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK15107189.9A HK1206752A1 (zh) 2009-02-18 2015-07-28 特異性結合蛋白及其用途
HK16102177.3A HK1214278A1 (zh) 2009-02-18 2016-02-25 特異性結合蛋白及其用途

Country Status (34)

Country Link
US (6) US20100056762A1 (zh)
EP (3) EP3301117A3 (zh)
JP (6) JP5859314B2 (zh)
KR (7) KR20180125044A (zh)
CN (3) CN104650232B (zh)
AU (4) AU2010216168B2 (zh)
BR (1) BRPI1012340B1 (zh)
CA (1) CA2752584C (zh)
CL (2) CL2011002003A1 (zh)
CO (1) CO6420350A2 (zh)
CY (2) CY1124849T1 (zh)
DK (2) DK2398828T3 (zh)
DO (1) DOP2020000032A (zh)
EC (1) ECSP11011335A (zh)
ES (2) ES2645663T3 (zh)
GT (1) GT201100223A (zh)
HK (3) HK1206752A1 (zh)
HR (2) HRP20150656T1 (zh)
HU (2) HUE025435T2 (zh)
IL (1) IL214643A (zh)
LT (1) LT2913344T (zh)
MX (3) MX2011008767A (zh)
MY (2) MY185858A (zh)
NO (1) NO2913344T3 (zh)
NZ (4) NZ627103A (zh)
PE (3) PE20120569A1 (zh)
PH (1) PH12014502419A1 (zh)
PL (2) PL2398828T3 (zh)
PT (2) PT2398828E (zh)
RU (3) RU2673724C2 (zh)
SG (3) SG10201407281UA (zh)
SI (2) SI2913344T1 (zh)
UA (2) UA117807C2 (zh)
WO (1) WO2010096434A2 (zh)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
EP2335728A1 (en) 2001-05-11 2011-06-22 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
CN104043123B (zh) * 2007-01-25 2019-08-13 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
CN101688229B (zh) * 2007-03-15 2013-06-12 路德维格癌症研究所 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
CN101896503B (zh) 2007-08-14 2018-05-22 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
MX2010011955A (es) * 2008-04-29 2011-01-21 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
US8314151B2 (en) 2008-04-29 2012-11-20 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, and processes for using same
NZ589436A (en) * 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MX2010013239A (es) * 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
CN102149825B (zh) * 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
EP2362908A4 (en) 2008-11-03 2013-09-18 Alethia Biotherapeutics Inc ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PE20121530A1 (es) * 2009-09-01 2012-12-22 Abbvie Inc Inmunoglobulinas con dominio variable dual
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
JP2013507928A (ja) * 2009-10-15 2013-03-07 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20160186188A1 (en) * 2010-02-09 2016-06-30 Rutgers, The State University Of New Jersey Methods for altering polypeptide expression and solubility
WO2012018790A2 (en) 2010-08-03 2012-02-09 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
US9051370B2 (en) 2010-08-10 2015-06-09 Glycotope Gmbh Humanized EGFR antibodies
EP2603527A1 (en) * 2010-08-10 2013-06-19 Glycotope GmbH Humanized egfr antibodies
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
EP2670426B1 (en) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
CA2888908A1 (en) * 2011-03-31 2012-10-04 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
US8911992B2 (en) * 2011-04-28 2014-12-16 Bio-Rad Laboratories, Inc. DNA removal in target molecule purification
BR112014015851A2 (pt) 2011-12-30 2019-09-24 Abbvie Inc proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
JP6282597B2 (ja) 2012-01-09 2018-02-21 アー・デー・ツェー・セラピューティクス・エス・アー 乳癌を治療する方法
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
EP3473708B1 (en) 2012-07-24 2021-01-27 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
WO2014035474A1 (en) * 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
EP2912467A4 (en) * 2012-10-26 2016-04-20 Univ Queensland METHODS FOR CLASSIFYING TUMORS AND USES THEREOF
KR20210111353A (ko) 2012-11-01 2021-09-10 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
MX2015013166A (es) 2013-03-15 2015-12-11 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
CN104087607B (zh) * 2013-04-01 2017-06-20 科济生物医药（上海）有限公司 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞
DK3030581T3 (da) * 2013-08-07 2021-04-12 Affimed Gmbh Antistofbindingssteder, der er specifikke for egfrviii
PL3126388T3 (pl) 2014-03-11 2019-10-31 Regeneron Pharma Przeciwciała anty-egfrviii i ich zastosowania
IL295906A (en) * 2014-03-21 2022-10-01 Abbvie Inc Antibodies against egfr and drug antibody conjugates
KR102110187B1 (ko) 2014-05-14 2020-05-14 카르스젠 테라퓨틱스 리미티드 키메라 항원 수용체 단백질을 코딩하는 핵산 및 키메라 항원 수용체 단백질을 발현하는 t 림프구
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN106349389B (zh) * 2015-07-21 2019-11-15 科济生物医药（上海）有限公司 肿瘤特异性抗egfr抗体及其应用
US10768794B2 (en) 2015-12-21 2020-09-08 Sap Se Truncated synchronization of data object instances
US11360997B2 (en) 2015-12-21 2022-06-14 Sap Se Data synchronization error resolution based on UI manipulation actions
JP2019521106A (ja) 2016-06-08 2019-07-25 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体薬物コンジュゲート
TWI762487B (zh) 2016-06-08 2022-05-01 美商艾伯維有限公司 抗-b7-h3抗體及抗體藥物結合物
US20190153108A1 (en) 2016-06-08 2019-05-23 Abbvie Inc. Anti-egfr antibody drug conjugates
JP2019521114A (ja) 2016-06-08 2019-07-25 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体薬物コンジュゲート
EP3528798A4 (en) 2016-10-19 2020-10-21 United States Government as Represented by The Department of Veterans Affairs COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
US11285154B2 (en) 2017-03-29 2022-03-29 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating cancer
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
CA3061201A1 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
CN107974461A (zh) * 2018-01-18 2018-05-01 东北农业大学 一种高效表达anti-hEGFR基因的真核表达载体构建方法
CN108220244A (zh) * 2018-01-18 2018-06-29 东北农业大学 一种含重组人表皮生长因子受体抗体基因的cho细胞株、筛选方法及其生产工艺
CN108250297B (zh) * 2018-01-23 2021-07-23 上海生物制品研究所有限责任公司 抗egfr抗体、其制法及其应用
EP3941947A4 (en) * 2019-03-22 2022-12-14 Olivia Newton-John Cancer Research Institute ANTI-HER2 BINDING MOLECULES
EP4117788A4 (en) * 2020-03-11 2024-04-10 UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF VETERANS AFFAIRS COMBINED INHIBITION OF EGFR AND NRF2 IN THE TREATMENT OF MALIGNANT GLIOM
WO2022068870A1 (zh) * 2020-09-30 2022-04-07 中国科学院动物研究所 靶向egfr的嵌合抗原受体
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022271722A1 (en) 2021-06-22 2022-12-29 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibody drug conjugates and uses thereof

Family Cites Families (300)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US439912A (en) 1890-11-04 Shutter worker
USRE31006E (en) 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4162940A (en) 1977-03-31 1979-07-31 Takeda Chemical Industries, Ltd. Method for producing Antibiotic C-15003 by culturing nocardia
US4169888A (en) 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4263294A (en) 1978-11-20 1981-04-21 Takeda Chemical Industries, Ltd. Maytansinoids, pharmaceutical compositions thereof and method of use thereof
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5622790A (en) 1979-07-31 1981-03-03 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
EP0043718B1 (en) 1980-07-07 1984-11-28 National Research Development Corporation Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4413132A (en) 1980-11-18 1983-11-01 The Upjohn Company Antibiotic CC-1065 indoline intermediates
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4451570A (en) 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
FR2523445A1 (fr) 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
US4418064A (en) 1982-09-29 1983-11-29 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
EP0171407B1 (en) 1984-01-30 1993-11-18 Imperial Cancer Research Technology Limited Improvements relating to growth factors
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5851526A (en) 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4997913A (en) 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
IN165717B (zh) 1986-08-07 1989-12-23 Battelle Memorial Institute
USRE38008E1 (en) 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5034223A (en) 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5047324A (en) 1986-12-09 1991-09-10 Miles Inc. Substantially pure enzyme-antibody conjugate preparations
US5332837A (en) 1986-12-19 1994-07-26 The Upjohn Company CC-1065 analogs
US4952394A (en) 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US4937183A (en) 1988-02-03 1990-06-26 Cytogen Corporation Method for the preparation of antibody-fragment conjugates
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
EP0329184A3 (en) 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
KR0137959B1 (ko) 1988-09-12 1998-05-15 로버트 에이. 아미테이지 2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5171563A (en) 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
DE68909416T2 (de) 1988-10-12 1994-03-24 Centocor Inc Radiotherapeutische immunokonjugate, etikettiert mit iod-125.
CA2006408A1 (en) 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
US5217713A (en) 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
US5013547A (en) 1989-02-07 1991-05-07 Erbamont, Inc. Anticancer drug - antibody conjugates and method for preparing same
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5980896A (en) 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
DE69025946T2 (de) * 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5459061A (en) * 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
AU656518B2 (en) 1990-02-20 1995-02-09 Coulter Corporation Improved antibody-enzyme direct conjugates and method of making same
AU7774391A (en) 1990-04-20 1991-11-11 Ludwig Institute For Cancer Research Aberrant, epidermal growth factor receptor dna, rna and protein forms and method
EP0527189A1 (en) 1990-04-25 1993-02-17 PHARMACIA & UPJOHN COMPANY Novel cc-1065 analogs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US6248332B1 (en) 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
FI101678B1 (fi) 1990-12-31 1998-08-14 Akzo Nv Happolabiileja kytkentämolekyylejä
SK281142B6 (sk) 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Humanizovaná monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
ES2134212T3 (es) * 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6797492B2 (en) * 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
DE69327620T2 (de) 1992-08-18 2000-08-03 Immunologia Molecular Ciudad D Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5674977A (en) 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
PT749325E (pt) 1994-03-07 2002-11-29 Medarex Inc Mpleculas biespecificas possuindo utilidades clinicas
AU2071695A (en) 1994-03-17 1995-10-03 Merck Patent Gmbh Anti-EGFR single-chain FVS and anti-EGFR antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US5612474A (en) 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
US5911995A (en) 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
JP4620808B2 (ja) 1994-11-28 2011-01-26 トーマス・ジェファーソン・ユニバーシティ 突然変異上皮成長因子受容体を標的とする試薬および方法
JP3607407B2 (ja) 1995-04-26 2005-01-05 株式会社日立製作所 半導体記憶装置
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
WO1997012862A1 (en) 1995-10-03 1997-04-10 The Scripps Research Institute Cbi analogs of cc-1065 and the duocarmycins
US6699715B1 (en) 1995-11-30 2004-03-02 Bristol-Myers Squibb Co. Modified sFv molecules which mediate adhesion between cells and uses thereof
PT871490E (pt) 1995-12-22 2003-07-31 Bristol Myers Squibb Co Ligantes de hidrazona ramificada
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
EP0934269A4 (en) 1996-05-31 2000-01-12 Scripps Research Inst CC-1065 ANALOGS AND DUOCARMYCINS
US5708156A (en) * 1996-05-31 1998-01-13 Ilekis; John V. Epidermal growth factor receptor-like gene product and its uses
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
JP2002503228A (ja) 1997-05-22 2002-01-29 ザ スクリップス リサーチ インスティテュート デュオカルマイシンおよびｃｃ−１０６５の類似体
CA2300071C (en) 1997-09-12 2009-04-07 Lumigen, Inc. Novel compounds for generating chemiluminescence with a peroxidase
JP2001519412A (ja) 1997-10-14 2001-10-23 ザ スクリップス リサーチ インスティテュート Ｃｃ−１０６５およびデュオカルマイシンのイソ−ｃｂｉおよびイソ−ｃｉ類似体
IL136489A0 (en) 1997-12-08 2001-06-14 Scripps Research Inst Synthesis of cc-1065/duocarmycin analogs
US6464686B1 (en) 1998-01-21 2002-10-15 Abbott Laboratories Polyurethane feeding tube and associated adaptors
CA2316860A1 (en) 1998-02-06 1999-08-12 Ilexus Pty. Limited Three-dimensional structures and models of fc receptors and uses thereof
US7553809B2 (en) 1998-02-06 2009-06-30 Ilexus Pty Limited Fc receptor modulators and uses thereof
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US20030224001A1 (en) 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
CA2327505A1 (en) 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
AUPP380498A0 (en) 1998-05-29 1998-06-25 Biomolecular Research Institute Limited Egf receptor agonists and antagonists
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US20030215387A1 (en) 1998-09-04 2003-11-20 Peter Harrison Bifunctional antibodies and their use in targeting anti-tumour agents
AU769489B2 (en) 1998-09-11 2004-01-29 Ilexus Pty Limited Fc receptor modulators and uses thereof
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
SK16522001A3 (sk) 1999-05-14 2002-10-08 Imclone Systems Incorporated Liečivo na inhibíciu rastu refraktérnych nádorov
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
NZ517772A (en) 1999-11-24 2004-03-26 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
WO2001062931A2 (en) 2000-02-25 2001-08-30 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF
CA2408175A1 (en) 2000-03-10 2001-09-20 Thomas Jefferson University Sensitive detection of wild-type and mutant egfr by specific elisa assays in any biological sample
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
CN100390288C (zh) 2000-04-11 2008-05-28 杰南技术公司 多价抗体及其应用
US6495599B2 (en) 2000-04-13 2002-12-17 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses therof
AU2001273983A1 (en) 2000-05-02 2001-11-12 Lutz F. Tietze Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo(3,2-e)indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo(f)quinoline derivatives for use in selective cancer therapy
KR20030007640A (ko) 2000-05-19 2003-01-23 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석
AUPQ841800A0 (en) 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
WO2002011677A2 (en) 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
AR030612A1 (es) 2000-09-12 2003-08-27 Smithkline Beecham Corp Procedimiento e intermedios
JP5010089B2 (ja) 2000-09-19 2012-08-29 スピロジェン リミテッド Ｃｃ−１０６５およびデュオカルマイシンのアキラルアナログの組成物およびその使用方法
DE10048417A1 (de) 2000-09-29 2002-04-11 Roche Diagnostics Gmbh Verbindungen mit verzweigtem Linker
EP1326859A1 (en) 2000-10-13 2003-07-16 AstraZeneca AB Quinazoline derivatives with anti-tumour activity
CN100488563C (zh) 2001-02-19 2009-05-20 默克专利有限公司 免疫原性降低的经修饰抗egfr抗体
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US20020156274A1 (en) 2001-03-16 2002-10-24 Terfloth Gerald J. Process for preparing maytansinol
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
JP2004528368A (ja) 2001-05-08 2004-09-16 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗ｅｇｆｒ抗体と抗ホルモン剤を用いた組合せ療法
EP2335728A1 (en) 2001-05-11 2011-06-22 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20110313230A1 (en) * 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
KR20030033007A (ko) 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
KR20090125840A (ko) 2001-06-13 2009-12-07 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간 모노클로날 항체
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20050107595A1 (en) 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20040248196A1 (en) 2001-08-03 2004-12-09 Adams Timothy Edward Methods of screening based on the egf receptor crystal structure
DE10138876B4 (de) 2001-08-08 2008-11-06 Forschungszentrum Jülich GmbH Genetisch modifizierte zyklisch-Nukleotid-gesteuerte lonenkanäle und deren Verwendung
CA2459308A1 (en) 2001-09-07 2003-03-20 Dale L. Boger Cbi analogues of cc-1065 and the duocarmycins
US20030109682A1 (en) 2001-09-07 2003-06-12 Daniel Santi Maytansines and maytansine conjugates
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US20040241703A1 (en) 2002-08-19 2004-12-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1458737A4 (en) 2001-11-21 2006-03-29 Univ Washington BIOSYNTHETIC MULTIGENIC FAMILY FOR ANTI-TUMOR AGENT ANSAMITOCIN MAYTANSINOIDE
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
EP1467758A4 (en) 2002-01-03 2007-11-14 Smithkline Beecham Corp PREPARATION OF IMMUNOCONJUGATES
US6790954B2 (en) 2002-01-29 2004-09-14 Immunogen, Inc. Mutant Actinosynnema pretiosum strain with increased maytansinoid production
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
US20050222059A1 (en) 2002-02-25 2005-10-06 Tang Careen K Egfrviii specific monoclonal antibody and egfrviii ribozymes and use to detect, treat or prevent egfrviii associated cancer
JP2005520539A (ja) 2002-03-19 2005-07-14 ザ・ペン・ステート・リサーチ・ファンデーション Ｅｇｆｒリガンドおよび使用方法
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6534660B1 (en) 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
NZ536271A (en) 2002-05-13 2008-01-31 Smithkline Beecham Corp Process for preparing maytansinol
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
PL375064A1 (en) 2002-05-20 2005-11-14 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
WO2003101491A1 (fr) 2002-06-03 2003-12-11 Mitsubishi Pharma Corporation Moyens preventifs et/ou therapeutiques destines a des sujets presentant l'expression ou l'activation de her2 et/ou egfr
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP2366718A3 (en) 2002-06-28 2012-05-02 Domantis Limited Ligand
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
KR20050032110A (ko) 2002-08-02 2005-04-06 이뮤노젠 아이엔씨 신규의 효능을 갖는 탁산을 포함하는 세포독성제 및 그치료용도
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
AU2003259163B2 (en) 2002-08-16 2008-07-03 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
AU2003276084B2 (en) 2002-10-10 2009-07-09 Merck Patent Gmbh Bispecific anti-Erb-B antibodies and their use in tumor therapy
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
US20040147428A1 (en) 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
EP1622941A2 (en) 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
CA2450289A1 (en) 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
US7432088B2 (en) 2003-05-08 2008-10-07 Immunogen Inc. Methods for the production of ansamitocins
WO2004101767A2 (en) 2003-05-13 2004-11-25 The Scripps Research Institute Cbi analogues of the duocarmycins and cc-1065
US7374762B2 (en) 2003-05-14 2008-05-20 Immunogen, Inc. Drug conjugate composition
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
KR20160003332A (ko) 2003-06-27 2016-01-08 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
EP1694706B1 (en) * 2003-11-01 2012-04-04 Merck Patent GmbH Modified anti-cd52 antibody
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US20050142133A1 (en) 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
AU2004309347B2 (en) 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
WO2005070457A1 (en) 2004-01-23 2005-08-04 Seattle Genetics, Inc. Melphalan prodrugs
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
ES2533695T3 (es) 2004-03-02 2015-04-14 Seattle Genetics, Inc. Anticuerpos cargados parcialmente y métodos para su conjugación
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
DK1735348T3 (da) 2004-03-19 2012-07-16 Imclone Llc Humant anti-epidermalt vækstfaktorreceptorantistof
AU2005227326B2 (en) 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
JP4350148B2 (ja) 2004-03-31 2009-10-21 ザ ジェネラル ホスピタル コーポレイション 上皮細胞成長因子受容体ターゲティング治療に対する癌の応答性を決定する方法
WO2005099754A2 (en) 2004-04-14 2005-10-27 The Ohio State University Research Foundation Maytansinoid analogs as antitumor agents
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
CA2564076C (en) 2004-05-19 2014-02-18 Medarex, Inc. Chemical linkers and conjugates thereof
CN102973947A (zh) 2004-06-01 2013-03-20 健泰科生物技术公司 抗体-药物偶联物和方法
ES2564127T5 (es) 2004-06-04 2020-03-26 Genentech Inc Mutaciones en EGFR
AU2005267720B2 (en) * 2004-08-05 2012-02-23 Genentech, Inc. Humanized anti-cmet antagonists
US20060029574A1 (en) 2004-08-06 2006-02-09 Board Of Regents, The University Of Texas System Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity
BRPI0516284A (pt) 2004-09-23 2008-09-02 Genentech Inc anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ES2715776T3 (es) 2004-11-12 2019-06-06 Seattle Genetics Inc Auristatinas que tienen una unidad de ácido aminobenzoico en el extremo N
EP1817341A2 (en) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
EP1688415A1 (en) 2004-12-07 2006-08-09 Aventis Pharma S.A. Cytotoxic agents comprising new C-2 modified taxanes
EP1669358A1 (en) 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
RU2007125644A (ru) 2004-12-07 2009-01-20 Дженентек Инк. (Us) Отбор пациентов для терапии ингибитором her
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
ES2503719T3 (es) 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
EA200702143A1 (ru) 2005-04-01 2008-06-30 Эмджен Инк. Способы прогнозирования эффективности и лечения рака по увеличенному числу копий гена
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
PL1912671T3 (pl) 2005-07-18 2018-02-28 Seattle Genetics, Inc. Koniugaty beta-glukuronid-linker-lek
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
EP1909846B1 (en) 2005-08-05 2018-12-26 Syntarga B.V. Triazole-containing releasable linkers, conjugates comprising the same and processes for their preparation
CA2617953C (en) 2005-08-09 2013-12-17 Millennium Pharmaceuticals, Inc. Method of acylating maytansinol with chiral amino acids
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PL1928503T3 (pl) 2005-08-24 2012-12-31 Immunogen Inc Sposób wytwarzania koniugatów majtazynoid-przeciwciało
JP5290756B2 (ja) 2005-09-26 2013-09-18 メダレックス インコーポレイテッド 抗体−薬剤コンジュゲート及びその使用
US7847105B2 (en) 2005-10-26 2010-12-07 Medarex, Inc. Methods and compounds for preparing CC-1065 analogs
ATE540956T1 (de) 2005-11-08 2012-01-15 Immunogen Inc Verfahren zur herstellung von maytansinol
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
JP2009515852A (ja) 2005-11-11 2009-04-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｅｇｆｒ／ｈｅｒ２インヒビターを含む癌の組み合わせ治療
ATE461220T1 (de) 2005-11-12 2010-04-15 Lilly Co Eli Anti-egfr-antikörper
AU2006332212B8 (en) 2006-01-04 2013-05-30 Institut National De La Sante Et De La Recherche Medicale Combination therapy using anti-EGFR and anti-HER2 antibodies
CA2641899A1 (en) 2006-02-02 2007-08-09 Syntarga B.V. Water-soluble cc-1065 analogs and their conjugates
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
EP1832577A1 (en) 2006-03-07 2007-09-12 Sanofi-Aventis Improved prodrugs of CC-1065 analogs
EP1996193A2 (en) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
CA2664327A1 (en) 2006-09-15 2008-03-20 Lifescience Pharmaceuticals Method for detecting and treating skin disorders
AU2007317333A1 (en) 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
US7790164B2 (en) 2006-11-14 2010-09-07 Van Andel Research Institute Fragments of antibodies to epidermal growth factor receptor and methods of their use
AU2007353412A1 (en) 2006-11-21 2008-11-20 Fox Chase Cancer Center Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
US20100034808A1 (en) * 2006-11-21 2010-02-11 Toru Nakazawa Compositions and methods for preserving cells of the eye
CN104043123B (zh) 2007-01-25 2019-08-13 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
CN101688229B (zh) 2007-03-15 2013-06-12 路德维格癌症研究所 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
WO2008152537A2 (en) 2007-06-14 2008-12-18 Zenotech Laboratories Limited Humanized monoclonal antibodies against human epidermal growth factor receptor, use and method thereof
US20100322939A1 (en) 2007-06-21 2010-12-23 Genmab A/S Novel methods for treating egfr-associated tumors
CA2695297C (en) 2007-08-01 2017-03-21 Syntarga B.V. Substituted cc-1065 analogs and their conjugates
CN101896503B (zh) 2007-08-14 2018-05-22 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
US20090269343A1 (en) 2008-04-11 2009-10-29 Duke University Dual Specific Immunotoxin for Brain Tumor Therapy
KR20210005318A (ko) 2008-04-30 2021-01-13 이뮤노젠 아이엔씨 가교제 및 그 용도
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
NZ594177A (en) 2009-02-05 2014-02-28 Immunogen Inc Novel benzodiazepine derivatives
BRPI1012195A2 (pt) 2009-05-01 2018-04-24 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
JP5680087B2 (ja) 2009-09-22 2015-03-04 シャンハイ・イージェー・バイオテクノロジー・カンパニー、リミテッドＳｈａｎｇｈａｉ Ｙｉｊｉｅ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ 特異的結合タンパク質およびその使用
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
JP2012518039A (ja) 2012-08-09
PE20200609A1 (es) 2020-03-10
PH12014502419A1 (en) 2017-06-05
US9072798B2 (en) 2015-07-07
EP2398828B1 (en) 2015-03-25
HK1214278A1 (zh) 2016-07-22
US20240117073A1 (en) 2024-04-11
JP6199269B2 (ja) 2017-09-20
PL2398828T3 (pl) 2015-08-31
PL2913344T3 (pl) 2018-02-28
KR20150093865A (ko) 2015-08-18
KR20180125044A (ko) 2018-11-21
US20210032366A1 (en) 2021-02-04
ES2645663T3 (es) 2017-12-07
CY1124849T1 (el) 2022-07-22
KR20110122848A (ko) 2011-11-11
RU2549678C2 (ru) 2015-04-27
CN105399829A (zh) 2016-03-16
KR20220025913A (ko) 2022-03-03
JP2022137018A (ja) 2022-09-21
BRPI1012340A (pt) 2017-07-25
CY1119591T1 (el) 2018-03-07
AU2015255246B2 (en) 2017-09-14
HUE025435T2 (en) 2016-04-28
NO2913344T3 (zh) 2017-12-30
UA106607C2 (uk) 2014-09-25
CN102405235A (zh) 2012-04-04
CA2752584A1 (en) 2010-08-26
MX361876B (es) 2018-12-18
BRPI1012340B1 (pt) 2021-06-01
CA2752584C (en) 2015-11-24
PE20160535A1 (es) 2016-06-10
MY165583A (en) 2018-04-05
CL2015003090A1 (es) 2016-07-22
JP2018148887A (ja) 2018-09-27
AU2010216168B2 (en) 2015-08-13
KR101809441B1 (ko) 2017-12-15
RU2018130075A (ru) 2020-02-20
MX2011008767A (es) 2011-11-02
US20100056762A1 (en) 2010-03-04
EP2913344A1 (en) 2015-09-02
DOP2020000032A (es) 2020-02-28
EP3301117A3 (en) 2018-07-25
RU2018130075A3 (zh) 2022-04-29
KR20210028271A (ko) 2021-03-11
PT2398828E (pt) 2015-06-30
KR101921046B1 (ko) 2018-11-23
JP2015043778A (ja) 2015-03-12
KR20190076069A (ko) 2019-07-01
BRPI1012340A8 (pt) 2018-01-02
JP2020195368A (ja) 2020-12-10
HK1206752A1 (zh) 2016-01-15
US20180057606A1 (en) 2018-03-01
JP6317780B2 (ja) 2018-04-25
DK2913344T3 (da) 2017-11-06
WO2010096434A3 (en) 2011-01-27
SG10201407281UA (en) 2014-12-30
SG10201801945TA (en) 2018-04-27
GT201100223A (es) 2013-11-21
PE20120569A1 (es) 2012-06-14
NZ716762A (en) 2017-09-29
UA117807C2 (uk) 2018-10-10
DK2398828T3 (en) 2015-04-27
EP2913344B1 (en) 2017-08-02
NZ595224A (en) 2013-04-26
SG173688A1 (en) 2011-09-29
LT2913344T (lt) 2017-09-25
NZ608773A (en) 2014-10-31
CN104650232B (zh) 2018-06-05
RU2014120536A (ru) 2015-11-27
SI2913344T1 (sl) 2017-10-30
CL2011002003A1 (es) 2012-05-25
CO6420350A2 (es) 2012-04-16
AU2015255246A1 (en) 2015-12-03
WO2010096434A2 (en) 2010-08-26
SI2398828T1 (sl) 2015-07-31
EP2398828A2 (en) 2011-12-28
CN102405235B (zh) 2016-02-24
CN104650232A (zh) 2015-05-27
JP2016188209A (ja) 2016-11-04
ECSP11011335A (es) 2011-12-30
RU2011138154A (ru) 2013-03-27
AU2010216168A1 (en) 2011-09-29
HRP20150656T1 (hr) 2015-07-31
HRP20171636T1 (hr) 2017-12-15
EP3301117A2 (en) 2018-04-04
PT2913344T (pt) 2017-11-14
NZ627103A (en) 2016-03-31
US20160046726A1 (en) 2016-02-18
ES2540802T3 (es) 2015-07-13
MY185858A (en) 2021-06-14
IL214643A (en) 2016-10-31
JP5859314B2 (ja) 2016-02-10
US20120183471A1 (en) 2012-07-19
HUE037061T2 (hu) 2018-08-28
MX2018015915A (es) 2020-09-02
IL214643A0 (en) 2011-11-30
AU2017276184A1 (en) 2018-01-18
KR101579769B1 (ko) 2015-12-28
RU2673724C2 (ru) 2018-11-29
AU2021201724A1 (en) 2021-04-15
KR20170082653A (ko) 2017-07-14

Similar Documents

Publication Publication Date Title
HK1220706A1 (zh) 特異性結合蛋白及其用途
HRP20160819T1 (hr) Proteini koji vežu heterodimere i njihove uporabe
EP2481754A4 (en) SPECIFIC BINDING PROTEINS AND USES THEREOF
EP2655415A4 (en) THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
HK1200320A1 (zh) 結合蛋白
EP2654792A4 (en) HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
IL222961A0 (en) Novel dna-dinding proteins and uses thereof
IL219202A0 (en) Il-1 binding proteins
IL214341A0 (en) Il-1 binding proteins
ZA201100058B (en) Prostaglandin e2 binding proteins and uses thereof
GB0916578D0 (en) Polypeptides and uses thereof
GB0916576D0 (en) Polypeptides and uses thereof
IL215291A0 (en) NOVEL ANTI-a5BETA1 ANTIBODIES AND USES THEREOF
IL216261A0 (en) IL-13 binding protein
IL220536A0 (en) Anti - bv8 antibodies and uses thereof
IL214527A0 (en) Anti-mst1r antibodies and uses thereof